ML-SI3 is a chemical compound which acts as an "antagonist" (i.e. channel blocker) of the
TRPML family of calcium channels, with greatest activity at the
TRPML1 channel, although it also blocks the related
TRPML2 and
TRPML3 channels with lower affinity. It is used for research into the role of TRPML1 and its various functions in
lysosomes and elsewhere in the body.[1][2][3][4][5][6][7]
^Li X, Rydzewski N, Hider A, Zhang X, Yang J, Wang W, et al. (April 2016). "A molecular mechanism to regulate lysosome motility for lysosome positioning and tubulation". Nature Cell Biology. 18 (4): 404–17.
doi:
10.1038/ncb3324.
hdl:2027.42/120892.
PMID26950892.
^Leser C, Keller M, Gerndt S, Urban N, Chen CC, Schaefer M, Grimm C, Bracher F (October 2020). "Chemical and pharmacological characterization of the TRPML calcium channel blockers ML-SI1 and ML-SI3". European Journal of Medicinal Chemistry: 112966.
doi:
10.1016/j.ejmech.2020.112966.
ML-SI3 is a chemical compound which acts as an "antagonist" (i.e. channel blocker) of the
TRPML family of calcium channels, with greatest activity at the
TRPML1 channel, although it also blocks the related
TRPML2 and
TRPML3 channels with lower affinity. It is used for research into the role of TRPML1 and its various functions in
lysosomes and elsewhere in the body.[1][2][3][4][5][6][7]
^Li X, Rydzewski N, Hider A, Zhang X, Yang J, Wang W, et al. (April 2016). "A molecular mechanism to regulate lysosome motility for lysosome positioning and tubulation". Nature Cell Biology. 18 (4): 404–17.
doi:
10.1038/ncb3324.
hdl:2027.42/120892.
PMID26950892.
^Leser C, Keller M, Gerndt S, Urban N, Chen CC, Schaefer M, Grimm C, Bracher F (October 2020). "Chemical and pharmacological characterization of the TRPML calcium channel blockers ML-SI1 and ML-SI3". European Journal of Medicinal Chemistry: 112966.
doi:
10.1016/j.ejmech.2020.112966.